Hydralazine/magnesium valproate off-label use

Hydralazine/magnesium valproate off-label use Reactions 1680, p159 - 2 Dec 2017 Hydralazine/magnesium valproate off- label use Skin rash: case report In a study, a patient [age and sex not stated] was described, who developed a skin rash following the off-label use of hydralazine and magnesium valproate [Transkrip; routes and time to reaction onset not stated; not all dosages stated]. The patient was diagnosed with myelodysplastic syndrome (MDS). The patient was started on combination therapy with daily dose hydralazine slow release formulation tablets and magnesium valproate slow release tablets 700mg, 30mg/kg three times daily for myelodysplastic syndrome; both drugs were administered 5 days a week. However, the patient developed a skin rash. The skin rash disappeared without any corrective treatment. Author comment: "The aim of this study is to evaluate the clinical efficacy and safety of hydralazine, [magnesium valproate] in a case series of MDS patients treated in a compassionate manner." "All patients were informed that the administration of this drug combination was off-label". "Most toxicity was transient, grade 1–2, and did not require dose reduction or interruption of treatment." "[O]nly one patient developed a skin rash that disappeared without treatment." Candelaria M, et al. Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIPTM) as epigenetic treatment for myelodysplastic syndrome (MDS). Annals of Hematology 96: 1825-1832, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1007/s00277-017-3103-x - Mexico 803284622 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Hydralazine/magnesium valproate off-label use

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/hydralazine-magnesium-valproate-off-label-use-8NKYQJpGPe
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39090-2
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial